Cancer Family
Pleural Mesothelial Neoplasm
CI-CAN-00000322Explore in graph →
Non-malignant34 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000322Explore in graph →
Clinical trials
157 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05278975 | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | completed | Phase 1 / Phase 2 | 50 | RS Oncology LLCINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04926948 | Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02959463 |
| Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma |
| completed |
| Phase 1 |
| 25 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| May 27, 2026 |
| clinicaltrials |
| NCT02399371 | Pembrolizumab in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 65 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03710876 | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma(INFINITE) | completed | Phase 3 | 53 | Ferring Ventures LimitedINDUSTRY | 9 | Apr 21, 2026 | clinicaltrials |
| NCT00797719 | Short Neoadjuvant Hemithoracic IMRT for MPM | completed | Phase 1 / Phase 2 | 104 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07449624 | From Presentation to Diagnosis: Patterns of Pleural Effusion | completed | — | 300 | Mansoura University HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT02662504 | Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma(MesoPDT) | completed | Phase 2 | 6 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04334759 | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma(DREAM3R) | completed | Phase 3 | 214 | PrECOG, LLC.OTHER | 3 | Jan 22, 2026 | clinicaltrials |
| NCT02611037 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05308966 | Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)(MESO-IMMUNE) | completed | — | 204 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04525859 | Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | completed | Phase 1 | 19 | Oncovir, Inc.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04040231 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02649829 | Autologous Dendritic Cell Vaccination in Mesothelioma(MESODEC) | completed | Phase 1 / Phase 2 | 28 | University Hospital, AntwerpOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04843007 | Alvopem® (Pemetrexed) Safety Assessment | completed | — | 199 | NanoAlvandINDUSTRY | 0 | Oct 23, 2024 | clinicaltrials |
| NCT01265433 | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | completed | Phase 2 | 41 | Sellas Life Sciences GroupINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05660616 | Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 40 | Ain Shams UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04324437 | eRAPID: Online Symptom Reporting in Lung Cancer | completed | N/A | 43 | University of LeedsOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT01486368 | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02899195 | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma(PrE0505) | completed | Phase 2 | 55 | PrECOG, LLC.OTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02414945 | TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients | completed | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02555007 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM(NVB Metro) | completed | Phase 1 | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT00652574 | Dasatinib in Resectable Malignant Pleural Mesothelioma | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT01865045 | Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients | completed | — | 150 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04775446 | Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy(MESOIMMUNE) | completed | — | 116 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | completed | Phase 2 | 42 | Swiss Cancer InstituteOTHER | 2 | Jul 14, 2021 | clinicaltrials |
| NCT02049060 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | completed | Phase 1 / Phase 2 | 31 | Armando Santoro, MDOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03048474 | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma(INITIATE) | completed | Phase 2 | 36 | The Netherlands Cancer InstituteOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01675765 | Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | completed | Phase 1 | 60 | Aduro Biotech, Inc.INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 40 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03412357 | MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.(MesoTRAP) | completed | N/A | 23 | Papworth Hospital NHS Foundation TrustOTHER_GOV | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01112293 | Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma | completed | Phase 2 | 14 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT00299962 | Gene Therapy for Pleural Malignancies | completed | Phase 1 | 17 | University of PennsylvaniaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02194231 | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)(ATREUS) | completed | Phase 2 | 145 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT01098266 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | completed | Phase 3 | 400 | AGC Biologics S.p.A.INDUSTRY | 12 | Sep 17, 2019 | clinicaltrials |
| NCT01722149 | Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | completed | Early Phase 1 | 4 | University of ZurichOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00484276 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma(NGR010) | completed | Phase 2 | 57 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01358084 | Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM(NGR019) | completed | Phase 2 | 137 | AGC Biologics S.p.A.INDUSTRY | 3 | Jan 15, 2019 | clinicaltrials |
| NCT02585362 | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | completed | N/A | 52 | Kantonsspital Winterthur KSWOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02397928 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | completed | Phase 2 | 82 | NovoCure Ltd.INDUSTRY | 7 | Sep 25, 2018 | clinicaltrials |
| NCT01160458 | Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Jul 24, 2026source: clinicaltrials